Beroctocog alfa
- Generic Name
- Beroctocog alfa
- Brand Names
- Alphanate
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 9001-27-8
- Unique Ingredient Identifier
- 17RNR4H479
- Indication
Beroctocog alfa is indicated for the prevention and control of bleeding in patients with hemophilia A or acquired Factor VIII (FVIII) deficiency. It is also indicated for surgical/invasive procedures in adult and pediatric patients with von Willebrand Disease in who desmopression is either ineffective or contraindicated. It is not indicated for patients with severe (i.e. type 3) von Willebrand Disease whom are undergoing major surgery.
- Associated Conditions
- Bleeding
- Associated Therapies
- Perioperative management therapy
Novo Nordisk to present new data highlighting innovative rare blood disorder treatments
Novo Nordisk presents new clinical data on sickle cell disease and hemophilia treatments at ASH 2024, including etavopivat's phase 2 results and Mim8 and concizumab's phase 3 trial outcomes, aiming to address unmet needs in rare blood disorders.
Hemophilia B Treatment Market 2034: EMA, PDMA, FDA Approvals
Hemophilia B market to grow significantly by 2034, driven by gene therapies like HEMGENIX and BEQVEZ, priced at $3.5 million each. Key companies include Centessa Pharmaceuticals, Sanofi, Pfizer, and Novo Nordisk. Market dynamics influenced by increasing prevalence, prophylactic treatment focus, and pipeline advancements.
Hemophilia A Clinical Trials 2024: EMA, PDMA, FDA Approvals, Pipeline, Therapies
DelveInsight's 'Hemophilia A Pipeline Insight 2024' covers global Hemophilia A therapies, highlighting over 40+ pipeline therapies, key companies like Spark Therapeutics, Pfizer, and Sanofi, and recent FDA approvals for Roctavian and ALTUVIIIO. The report assesses the therapeutic landscape, including product types, stages, routes of administration, and molecule types.
Hemophilia A Clinical Trials 2024: EMA, PDMA, FDA Approvals
DelveInsight's 'Hemophilia A Pipeline Insight 2024' covers global Hemophilia A therapies, highlighting over 40+ pipeline therapies, key companies like Spark Therapeutics, Pfizer, and Novo Nordisk, and recent FDA approvals for Roctavian and ALTUVIIIO.
HYMPAVZI Approved By FDA To Treat Hemophilia A Or B Without Inhibitors
The FDA approved Pfizer’s HYMPAVZI (marstacimab-hncq) for routine prophylaxis in hemophilia A or B without inhibitors, administered via a pre-filled auto-injector pen with a once-weekly dosing schedule. HYMPAVZI is the first anti-TFPI approved for hemophilia treatment in the U.S. and aims to reduce treatment burden with a manageable safety profile.
FDA Approves Pfizer's Second Hemophilia Drug With Six Months
FDA approves Pfizer's Hympavzi, the first anti-TFPI for hemophilia A or B, administered via an auto-injector pen, reducing bleeding episodes in patients. Expected sales of $300 million by 2030.
Pfizer's Hympavzi receives US FDA approval to treat adults and adolescents with ...
Pfizer's Hympavzi, an anti-TFPI approved by the FDA, offers a once-weekly subcutaneous treatment for hemophilia A or B without inhibitors, reducing bleeding episodes and treatment burden.
Pfizer Hemophilia drug Hympavzi Receives USFDA Approval
Pfizer's Hympavzi, a once-weekly injection for hemophilia A or B, received FDA approval. The drug, administered via auto-injector, aims to reduce bleeding episodes and treatment burden. Sales are projected to reach $300 million by 2030.
US FDA approves Pfizer's drug for rare bleeding disorder
Pfizer's Hympavzi, a once-a-week injection, received FDA approval for treating haemophilia A or B in patients aged 12 and older. The drug aims to reduce treatment burden and showed a 92% reduction in bleeding episodes in a late-stage study. Hympavzi is Pfizer's second haemophilia treatment approved this year, with potential sales of $300 million by 2030.
USFDA approves Pfizer's marstacimab-hncq for treatment of hemophilia A or B
FDA approves Pfizer's HYMPAVZI, the first anti-TFPI for hemophilia A or B, administered via a pre-filled auto-injector pen, offering a once-weekly subcutaneous treatment option.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath